How have the shares performed?
Accelerate Diagnostics Inc. (AXDX) saw an uptrend of 5.42% in the recent trading with $7.59 being its most recent. The current price level -60.28% lower than the highest price of $19.11 marked by the stock while trading over the past 52-weeks, whereas it is 15.09% higher than the lowest price of $6.59 the company dropped to over past 52-weeks. The latest news story on AXDX appeared in PR Newswire under the title “Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021” on May-19-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -4.41% below one month high and is +15.09% above of the lowest during that time. Looking into the simple moving average, Accelerate Diagnostics Inc. (AXDX)’s stock stands at a SMA-50 of $7.87 while that of 5-day is reading $7.10.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and AXDX’s SMA-200 as of now is $9.58.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 5 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.40 for the stock.
Accelerate Diagnostics Inc. Earnings – What Happened With AXDX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Accelerate Diagnostics Inc. (AXDX) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of -24.20% for net revenue. During the reported three-month period, company’s sales were $2.52 billion while analysts on average were estimating the same to be $3.07 million.
AXDX – Accelerate Diagnostics Inc. Stock Earnings Estimates
The perspective of Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.33 for stock’s EPS in the current quarter. 5 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.41.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 58.52 million. AXDX does have institutional investors; and they hold 41.60% of the stock.
Accelerate Diagnostics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 8 new insider purchases involving 193,892 shares. On the other hand, AXDX declared 116,761 shares have been sold in 10 insider transactions over the past three months.
Currently, the stock has been recommended as Moderate Buy by 5 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.40 for the stock.